Gemzar and Fosaprepitant dimeglumine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gemzar (gemcitabine hydrochloride) and Fosaprepitant dimeglumine (fosaprepitant dimeglumine). Common drug interactions include abdominal pain among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Gemzar and Fosaprepitant dimeglumine. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Fosaprepitant dimeglumine?

Fosaprepitant dimeglumine has active ingredients of fosaprepitant dimeglumine. eHealthMe is studying from 1,528 Fosaprepitant dimeglumine users. Check the latest studies of Fosaprepitant dimeglumine.

On Jul, 17, 2026

14 people who take Gemzar and Fosaprepitant dimeglumine together, and have interactions are studied.

Gemzar and Fosaprepitant dimeglumine drug interactions.

What are the common drug interactions of Gemzar and Fosaprepitant Dimeglumine, by gender? *:

female:

Abdominal pain
Asthenia (weakness)
Constipation
Dyspepsia (indigestion)
Herpes zoster
Hyperhidrosis (abnormally increased sweating)
Pancreatitis acute (sudden inflammation of pancreas)
Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
Cough
Dyspnoea (difficult or laboured respiration)

male:

Drug ineffective
Abdominal pain
White blood cell count decreased
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Ascites (accumulation of fluid in the abdominal cavity)
Diarrhoea
Hepatic failure (liver failure)
Hypokalaemia (low potassium)
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
Portal vein thrombosis (venous thrombosis affecting the hepatic portal vein)

What are the common drug interactions of Gemzar and Fosaprepitant Dimeglumine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Death

30-39:

n/a

40-49:

Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
Cough
Dyspnoea (difficult or laboured respiration)
Flushing (the warm, red condition of human skin)
Palpitations (feelings or sensations that your heart is pounding or racing)
Rash
Sensation of foreign body
Tremor (trembling or shaking movements in one or more parts of your body)

50-59:

Abdominal pain
Chest pain
Drug ineffective
Decreased appetite
Dyspepsia (indigestion)
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough)

60+:

Constipation
Dyspepsia (indigestion)
Pancreatitis acute (sudden inflammation of pancreas)
Ileus (a painful obstruction of the ileum or other part of the intestine)
White blood cell count decreased
Decreased appetite
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Ascites (accumulation of fluid in the abdominal cavity)
Diarrhoea
Hepatic failure (liver failure)

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 5 people, 35.71%
Diabetes: 4 people, 28.57%
Indigestion: 3 people, 21.43%
Cancer Pain: 3 people, 21.43%
Constipation: 3 people, 21.43%
Hypophagia (reduced food intake): 2 people, 14.29%
Bladder Cancer: 2 people, 14.29%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 2 people, 14.29%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 14.29%
Allergies: 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and Fosaprepitant dimeglumine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously